female founders

Houston health tech accelerator names annual cohort ahead of its pitch competition

Meet the female health tech founders being accelerated by Ignite Healthcare this year. Photo courtesy of Ignite

Last month, a Houston organization dedicated to supporting female founders in health care kicked off its 2023 accelerator with cohort participants from across the country.

Ignite Healthcare Network, based in Houston, is a nonprofit founded on the mission of supporting women in health care. Ignite established its 12-week accelerator program to help advance and connect female health tech founders with mentors and potential clients as their startups scale.

"We have 19 founders doing great work, and we have them matched with three to four advisors helping to mentor them," Ayse McCracken, founder and board chair of Ignite tells InnovationMap. "We also have a virtual learning program, which is new this year, and we have two sessions of those a week."

The programming is curated to tackle the health tech industry's biggest topics and provide advice for a small group of engaged startups, McCracken explains. In its fifth year now, the program has a large group of partners that are involved.

"We've had 91 companies come through our program in the last fours years," McCracken says. "They've raised over $550 million."

The cohort concludes on November 9 with the Fire Pitch Competition at the Ion, where a handful of finalists — selected by Ignite's team of mentors — will present to win the top award.

This year's cohort includes:

  • Somer Baburek, CEO and co-founder of Hera Biotech
  • Sue Carr, president and founder of CarrTech Corp
  • Suchismita Acharya, CEO, chief strategy officer, and co-founder of AyuVis
  • Asma Mirza, CEO and founder of Steradian Technologies
  • J’Vanay Santos, CEO and founder of MyLÚA Health
  • Maureen Brown, CEO and co-founder of Mosie Baby
  • Elizabeth Friedman, president and founder of Safen Medical Products
  • Meghan Doyle, CEO and co-founder of Partum Health
  • Marina Tarasova, COO and co-founder of Paloma Health
  • Melissa Bowley, CEO and founder of Flourish Care
  • Molly Hegarty, CEO and founder of Junum
  • Patty Lee, CEO and co-founder of Orbit Health
  • Piyush Modak, Vice President of R&D and co-founder of EndoMedix
  • Debbie Chen, CEO and founder of Hydrostasis
  • Rachael Grimaldi, CEO and co-founder of CardMedic
  • Rachna Dhamija, CEO of Ejenta
  • Carolyn Treviño Jenkins, CEO and co-founder of We Are Here
  • Lyn Markey, CEO and co-founder of XTremedy
  • Camille O’Malley, CTO and co-founder of XTremedy
Last year, Joanna Nathan, CEO of Houston-based Prana Thoracic, won the top award for her company.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted